10-Year CMS Cost Impact of Negotiated First-Line Suzetrigine Access

Net Cost Savings from Negotiated First-Line Access to Suzetrigine

Negotiating a lower price for suzetrigine in exchange for first-line access without patient or prescriber barriers generates large savings for CMS over the next ten years.

Incremental 10-year CMS savings versus status quo.

Increased Suzetrigine Adoption and Patient Impact

Avoided opioid prescriptions reduce the probability that a CMS beneficiary develops opioid use disorder.

Total opioid prescriptions in CMS are projected to be reduced by 39.4%–51.1% at year ten, from 58.6 million to 35.5 million with first-line access for acute pain and from 58.6 million to 28.7 million if chronic pain is added to the label as expected in 2027–2028.

Historical CMS opioid claims and modeled future opioid prescribing with and without first-line suzetrigine access.

Total new OUD cases prevented by suzetrigine adoption in CMS beneficiaries over the 10-year window, comparing status quo versus negotiated access.

Cumulative new OUD cases prevented by suzetrigine adoption in CMS beneficiaries, 2027–2036.

Cumulative OUD-attributable deaths avoided through suzetrigine adoption in CMS beneficiaries, 2027–2036.

Current Obstacles for Suzetrigine Adoption in CMS

Suzetrigine received FDA approval in January 2025 for moderate-to-severe acute pain. In its January and February 2026 public updates, Vertex said JOURNAVX had more than 550,000 prescriptions written and filled through year-end 2025. The main obstacles to adoption are:

Non-preferred coverage and cost sharing

In CMS, suzetrigine is currently treated as a non-preferred branded option that often carries materially higher patient cost sharing than a generic opioid. The model uses that gap as one of the reasons first-line uptake remains slow under current access conditions.

Prior authorization and launch-phase utilization management

Prescribers often face approval friction before dispensing suzetrigine in high-volume acute-pain settings.

Fail-first pressure toward cheaper analgesics

Opioids are cheap, already on every formulary, and sit as the default option in most acute-pain workflows. That makes them the path of least resistance over suzetrigine unless CMS explicitly removes the friction and encourages prescribing.

First-line access will dramatically increase adoption of suzetrigine

Our model is conservative about how quickly providers will switch from opioids to suzetrigine once first-line access is established. In practice, the transition could happen materially faster than modeled if prescriber workflows, formulary defaults, and patient demand all shift in the same direction.

Negotiated CMS net price per pill for each scenario, shown against the industry production COGS band ($0.20–$0.55/pill) and the $15.50 WAC list reference.

Share of CMS addressable opioid Rx receiving suzetrigine by year.

Annual suzetrigine prescriptions to CMS beneficiaries, 2027–2036.

What CMS spends on opioids today

CMS pays for the opioid prescriptions themselves (cheap per-Rx but large volume), and opioids drive refills and a non-OUD persistence tail that suzetrigine does not have, because it is non-addictive.

The mix below is the CASPR projection of which acute opioids suzetrigine most plausibly displaces. CASPR's own methodology labels this by-drug breakout as directional rather than a direct CMS drug-level audit: it starts with placeholder national drug shares, applies drug-specific acute/replaceable weights, and scales the result to the 50.4% addressable acute market.

Across the four most-prescribed acute opioid classes, roughly 50% of today's U.S. opioid prescriptions are plausibly substitutable by suzetrigine, with hydrocodone/APAP alone accounting for most of that pool. This figure reflects the acute-pain opportunity only; the substitutable pool expands further if and when suzetrigine's label extends to chronic pain use cases.

OUD-risk scores are directional 0–10 composites of DEA schedule, persistent-use rate vs. hydrocodone, per-drug OUD-progression literature, and abuse-liability data. Sources per drug in data/opioid_mix_costs.csv (column oud_risk_basis).

Does substitutability track inversely with addiction potential?

A reasonable concern is that the most substitutable opioids in the addressable pool might also be the least addictive, which would mute the OUD-prevention benefit of substitution. The volume-weighted numbers in the table say the opposite: the average OUD-risk score across the entire addressable pool is 5.82 / 10, and the average OUD-risk score across the prescriptions that would actually be substituted (each drug weighted by its share × substitutability) is 5.80 / 10. The two averages are essentially identical, which means substitution is not preferentially targeting the low-risk corner of the pool.

The intuition: hydrocodone/APAP is roughly 60% of the addressable acute pool by itself, is Schedule II, sits in the upper band of the OUD-risk score, and is highly substitutable. Oxycodone IR adds another 14% at higher OUD-risk and moderate substitutability. The lower-risk corner (codeine combinations, tramadol) is meaningful but not dominant, and the highest-risk corner (long-acting Schedule II) is barely substitutable but is also a small share of the acute pool. The distribution shown in the figure below reflects this directly.

Bubble area is proportional to each drug's share of the CMS acute substitutable pool. Substitution is not preferentially targeting low-risk drugs: the substitution-weighted average OUD risk is roughly equal to the pool average, so substitution-driven OUD prevention is not cosmetic.

Where is suzetrigine being prescribed today?

JOURNAVX has been on the market since January 2025 and Vertex's public disclosures sketch a real-world prescribing footprint that maps closely to the high-volume, opioid-naive acute pool the model targets. As of mid-October 2025, more than 300,000 prescriptions had been filled, including roughly 170,000 in Q3 2025 alone, on the way to more than 550,000 prescriptions by year-end 2025. Vertex has described the prescriber base as including orthopedic surgeons, plastic surgeons, anesthesiologists, pain specialists, and dentists, and the use settings as joint replacement and repair, shoulder surgeries, fractures and sprains, and dental procedures, across hospital and retail pharmacy channels. The clinical-trial program that supports the label is concentrated in the same setting (about 87% orthopedic-surgery patients in the open-label safety study, with the remainder in plastic, otorhinolaryngologic, general, and urologic surgery). Acute opioid initiation in opioid-naive adults in exactly these settings is the population the headline OUD-prevention rate (Brat BMJ 2018, ~0.6% per acute course) is calibrated on, so the live-market prescribing pattern is consistent with — not diluting — the modeled benefit.

Sources: Vertex Q3 2025 results, Vertex full-year 2025 results, VA Pharmacy Benefits Management monograph (May 2025), and the JOURNAVX prescribing information. Setting-level prescribing volumes are described qualitatively in Vertex disclosures; granular per-setting Rx counts are not publicly broken out yet.

Pricing Scenarios

A range of potential negotiated prices from a CMS-Vertex access deal, with first-line positioning exchanged for lower per-pill economics.

Basis for the StatusQuo price ($11/pill): Suzetrigine launched in January 2025 with a $15.50 WAC (Wholesale Acquisition Cost). The $11/pill StatusQuo figure is a modeling proxy for a current-access net price after typical launch-phase concessions and rebates; it is not a directly observed blended CMS net price. Actual Medicaid rebate mechanics and Medicare Part D net prices vary materially by state, plan, and contract.

Fiscal Impact of First-Line Suzetrigine Access

CMS savings come from two distinct sources. The smaller source is avoided opioid drug spend: the index Rx plus the refills and non-OUD escalation tail that suzetrigine does not have (suzetrigine is non-addictive, so refills are unnecessary). The much larger source is avoided CMS-paid OUD medical care.

10-year avoided CMS opioid drug spend comparing status quo versus negotiated first-line access, decomposed into index Rx cost (bottom, indigo) and refills plus non-OUD escalation (top, coral).

Gross CMS 10-year savings (before subtracting suzetrigine drug spend) comparing status quo versus negotiated first-line access. In both cases, avoided OUD medical care (top, indigo) dominates the fiscal line; avoided opioid drug spend (bottom two bars) is second-order. These bars show savings only; the offsetting cost of paying for suzetrigine is reported separately.

Annual CMS net fiscal impact (savings minus spend) by scenario, 2027–2036. Year 1 is modest because the prevented-OUD cohort starts small and the rolling medical-savings pool builds over time.

Where the savings accrue

The headline net-impact line is "CMS combined." That number is internally consistent for federal budget scoring, but the question of which stakeholder writes the smaller drug-spend check and pockets the much larger OUD medical-care savings matters for the politics of getting a deal done. Medicare Part D drug spend and Part D / Medicare Parts A and B medical savings sit on the federal balance sheet. Medicaid drug spend and Medicaid medical savings flow through the federal/state shared FMAP, so the gain accrues to two different appropriators. Vertex captures the suzetrigine net-price line. Society captures avoided productivity loss, criminal-justice cost, and lives saved on a separate accounting from the fiscal line.

Stakeholder breakdown of the Price2 ($2/pill) acute-only 10-year incremental impact vs. status quo. Federal Medicare Part D captures roughly 75% of the CMS net fiscal gain; federal Medicaid (FMAP share) captures another 17%; state Medicaid (non-federal share) captures the remaining 8%. Vertex captures incremental CMS-channel revenue. Societal benefits are shown separately and are not summed with the fiscal lines.

The political implication: the federal government captures the bulk of the fiscal upside (Medicare Part D + federal Medicaid ≈ 92% of the CMS line), while states share roughly 8% of the CMS upside on top of essentially the entire criminal-justice avoided cost (which is borne primarily by state and local governments). A blue state acting unilaterally on a Medi-Cal-only or CalPERS-only pathway can capture only its slice of the state-Medicaid line plus the criminal-justice and productivity benefits in its population. The federal Medicare/Medicaid lines are unavailable to a state-only deal. This stakeholder split is a major reason the federal pathway is the preferred channel where it is feasible; the state pathway is the right backstop and is analyzed in the companion California State Pathway Analysis.

Vertex Expected Revenue

In its January 11, 2026 and February 12, 2026 releases, Vertex said JOURNAVX had more than 550,000 prescriptions written and filled through year-end 2025, and prescription volume expected to more than triple in 2026 versus 2025. The company also guided to $500 million or more of combined 2026 non-CF product revenue across CASGEVY and JOURNAVX. Vertex did not, in those official materials, publish a JOURNAVX-only 2026 revenue target or a JOURNAVX-specific patent-life revenue forecast.

10-year Vertex CMS-channel revenue (indigo) and gross profit (teal) by pricing scenario, against this model's conservative status-quo baseline.

Potential Impact in Commercial Market

The core fiscal model is CMS-only, but the same policy could have meaningful spillover effects in the commercial market. If first-line use becomes routine in Medicare and Medicaid, that can reshape prescriber behavior, formulary expectations, and employer demand well beyond the public programs directly modeled here.

Commercial payers do not capture the full lifetime value of OUD prevention the way CMS does, because members often churn between plans and employers. Even so, lower opioid exposure can still matter financially through fewer refill cascades, lower short-run acute-care utilization, less disability, and less workplace disruption. The commercial opportunity should therefore be viewed both as a direct market opportunity for JOURNAVX and as a broader practice-pattern effect that could widen national adoption.

• Prescriber normalization matters. If CMS makes suzetrigine first-line in common acute-pain settings, clinicians gain familiarity using it in surgery, emergency care, dentistry, and primary care. Commercial prescribing could rise even without identical private-payer rules simply because the drug becomes part of routine care pathways.
• Employer economics differ from CMS economics. Commercial plans capture less of the long-tail OUD-prevention value because of churn, but employers still face meaningful near-term costs from opioid-related disability, absenteeism, and avoidable complications. That can still make opioid-sparing acute-pain treatment economically attractive.
• CMS can anchor private-market expectations. A large public deal could establish a reference point for price, access, and clinical expectations that commercial payers may partially follow. Even partial imitation in private formularies could materially expand total treated volume beyond the CMS-only numbers shown in this report.

Further Acceleration Strategies for Suzetrigine Adoption

CMS can do more than negotiate price and preferred placement. If the agency also uses implementation levers to make non-opioid prescribing routine at the point of care, the rate of adoption could increase materially, which would greatly expand both fiscal savings and societal benefits.

• Explicit first-line prescribing guidance. CMS could issue sub-regulatory guidance, preferred-drug recommendations, and quality-oriented communications that frame suzetrigine as the default first-line pharmacologic option for short-term acute pain in opioid-naive patients when clinically appropriate.
• Combination-therapy protocols with APAP. CMS could encourage standardized acute-pain pathways that pair suzetrigine with acetaminophen (APAP) before escalating to opioids, especially in common outpatient, dental, surgical, and emergency-department pain scenarios where multimodal analgesia is already familiar to prescribers.
• Opioid justification requirements for short-term acute pain. CMS or CMS-aligned plans could require prescribers to document why an opioid is being selected instead of suzetrigine for routine short-duration acute-pain use cases, creating a clear administrative nudge away from default opioid prescribing.
• Clinical decision-support and EHR defaults. CMS could work with health systems, Part D sponsors, Medicaid managed-care plans, and major EHR vendors to place suzetrigine-based acute-pain order sets higher in prescribing workflows and make opioid alternatives easier to choose in real time.
• Plan-performance incentives tied to opioid avoidance. CMS could build opioid-exposure reduction, non-opioid first-line use, or post-procedural opioid-sparing metrics into plan oversight and quality-improvement efforts so payers have operational reason to drive uptake instead of merely allowing it.
• Targeted provider education in high-volume acute-pain settings. Focused education for emergency medicine, primary care, dentistry, orthopedics, and ambulatory surgery could reduce launch-phase inertia and accelerate comfort with suzetrigine in exactly the settings that generate a large share of avoidable first opioid exposure.

Additional Fiscal Benefits from Likely Chronic-pain Label Expansion

Vertex is currently running two Phase 3 suzetrigine studies in painful diabetic peripheral neuropathy. In its August 4, 2025 results, Vertex said it would not advance painful lumbosacral radiculopathy into Phase 3 and would instead prioritize a second DPN Phase 3 study; in its January 11, 2026 pipeline update, Vertex said it expects to complete enrollment in both DPN studies by the end of 2026.

Illustrative upside comparison only: acute-pain label only (the base case) versus a future chronic-label scenario under the same simplified regimen structure.

Sensitivity

One-at-a-time sensitivity analysis on Price2 10-year CMS net impact. Each bar shows the result of a fresh Price2 model rerun with one assumption moved to its low or high setting.

Appendix 1: Societal impact of CMS action, separate from the CMS fiscal line

Components of 10-year value under Price2. The top bar is total CMS savings in the core fiscal line; the other three are societal externalities.

Appendix 2: Other Federal Channels

This section is supplemental. The core report is CMS-only. The VA, DoD/TRICARE, and IHS together fill millions of additional opioid prescriptions per year and could potentially benefit from similar pricing, but the estimates below are stylized directional extensions of the CMS framework rather than channel-specific actuarial forecasts.

Source basis for effective modeled $/OUD-yr column: Displayed values are effective modeled averages over the 10-year window, not raw annual source assumptions. VA = VA opioid stewardship reporting and VHA OUD utilization trends (VA News, 2023; JAMA Network Open, 2024). DoD/TRICARE = DHA/TRICARE enrollment and Military Health System pain-care framework synthesis (DHA TRICARE Numbers; Pain Medicine, 2023). IHS = IHS profile and opioid stewardship reporting (IHS Profile, Oct. 2024; IHS Opioid Stewardship Data).

Stylized appendix estimate: 10-year net fiscal impact across all four federal payers (CMS + VA + DoD + IHS) for each pricing scenario. Under these simplifying assumptions, federal channels beyond CMS add roughly 10% to the CMS-only fiscal line under the negotiated deal.

Appendix 3: Limitations in Typical CMS Drug Management Levers

These are important obstacles to consider when implementing this policy if maximum efficacy is the goal.

Appendix 4: Diversion-Seeded OUD Sensitivity

The core fiscal line counts only OUD developed by the index patient who receives an opioid prescription. It does not count OUD that develops in a non-recipient who later uses pills diverted from that patient's leftover supply. Suzetrigine has no diversion tail because it is non-addictive, has no street value, and produces no withdrawal or craving, so substituting suzetrigine for an opioid Rx prevents both the index-patient OUD risk (already in the model) and the diversion-seeded OUD risk (currently excluded). This appendix quantifies what the headline would look like if the diversion pathway were added at three literature-bracketed rates.

Why this is presented as an off-by-default sensitivity. No peer-reviewed study reports a single direct conversion rate from "leftover opioid pill" to "new OUD case in a non-recipient." Any quantitative estimate must layer multiple inputs (unused-pill rate, diversion rate, exposure-to-use rate, use-to-OUD rate), each carrying its own uncertainty. Including a layered estimate in the headline would create an attack surface in peer review. Reporting it as a sensitivity preserves the conservative posture of the core fiscal line while making the upside visible to the reader.

Two-step derivation

Bottom-up (Bicket-anchored). Start from Bicket et al., JAMA Surgery 2017: 42 to 71 percent of post-surgical opioid tablets are unused (use 60 percent central). Apply assumed downstream rates: roughly 15 percent of leftover pills reach a non-recipient (literature ranges; central estimate is conservative because most leftover pills go to disposal, hoarding by the patient, or take-back programs). Roughly 5 pills per first-exposure event (typical pattern from drug-use ethnography). Roughly 5 percent of first-exposure individuals progress to repeated nonmedical use, and roughly 7 to 10 percent of repeated nonmedical users develop OUD within several years (NSDUH cohort follow-ups; Florence et al. 2016). The resulting central estimate is approximately 0.20 percent per avoided Rx (sensitivity range 0.05 to 0.40 percent).

Top-down (NSDUH cross-check). The 2023 SAMHSA National Survey on Drug Use and Health reports approximately 8 to 9 million past-year nonmedical opioid users. The "source of misused pain reliever" question consistently shows that roughly half of those users obtained the drug from a friend or relative for free (the diversion pathway, as opposed to direct prescription, theft, or purchase). About 8 to 10 percent of past-year nonmedical users go on to develop OUD within several years. That implies roughly 360,000 to 450,000 new OUD cases per year with a diversion lineage. Dividing by the approximately 125 million annual U.S. opioid Rx gives an upper-bound rate of about 0.3 to 0.4 percent per Rx (this is an overestimate because not every diversion-lineage OUD case traces to a current-year prescription; some leftover pills date back many years). The two methods agree on the order of magnitude.

Sensitivity impact on Price2 headline

Adding the diversion-seeded OUD term at the three literature-bracketed rates lifts the Price2 incremental net CMS savings as follows. The base-case Price2 fiscal line is unchanged.

Assumptions

Methodology

Known limitations

Data Access